<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02196805</url>
  </required_header>
  <id_info>
    <org_study_id>009-09-801-01</org_study_id>
    <nct_id>NCT02196805</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study Comparing a Single Oral Intake of an Imported PROBUCOL Tablet(Lorelco) With a Marketed PROBUCOL Tablet(Chang Tai) in Chinese Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Beijing Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Beijing Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the pharmacokinetics characteristics of a single oral intake of an
      imported PROBUCOL tablet(Lorelco)(1*250mg/tablet) with a marketed PROBUCOL tablet (Chang
      Tai)(1*250mg/tablet) in healthy male volunteers to demonstrate they are bioequivalent.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BE parameters: AUC0-t</measure>
    <time_frame>blood sample will be collected at 4,8,12,16,24,36,48,72,96,144,216,288,360,456,552,648 hour of drug administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>BE parameters: Cmax</measure>
    <time_frame>blood sample will be collected at 4,8,12,16,24,36,48,72,96,144,216,288,360,456,552,648 hour of drug administration.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Cmax</measure>
    <time_frame>blood sample will be collected at 4,8,12,16,24,36,48,72,96,144,216,288,360,456,552,648 hour of drug administration.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Tmax</measure>
    <time_frame>blood sample will be collected at 4,8,12,16,24,36,48,72,96,144,216,288,360,456,552,648 hour of drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: AUC0-t</measure>
    <time_frame>blood sample will be collected at 4,8,12,16,24,36,48,72,96,144,216,288,360,456,552,648 hour of drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: AUC0-âˆž</measure>
    <time_frame>blood sample will be collected at 4,8,12,16,24,36,48,72,96,144,216,288,360,456,552,648 hour of drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: t1/2</measure>
    <time_frame>blood sample will be collected at 4,8,12,16,24,36,48,72,96,144,216,288,360,456,552,648 hour of drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chinese Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group A: imported Probucol ( Lorelco)</intervention_name>
    <description>Group A: take imported Probucol( Lorelco) (250mg/tablet), Qd, P.O.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group B: Marketed Probucol ( Chang Tai)</intervention_name>
    <description>Group B: take Marketed Probucol(Chang Tai)(250mg/tablet), Qd, P.O.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese Male, aged between 18 and 40 years (at time of informed consent), extremes
             included

          -  Non-smokers

          -  Normal weight as defined by a Quetelet body mass index range of 18.0 - 26.0 kg/m2,
             extremes included

          -  Subjects judged by the investigator or sub investigator to be healthy based on the
             physical examination, medical history, vital signs, electrocardiogram (ECG), and the
             results of clinical laboratory tests

          -  Provided signed informed consent prior to beginning protocol-specific procedures,
             indicating that they understood the purpose of this study

          -  Willing to adhere to the study procedures described in this protocol

        Exclusion Criteria:

          -  History of respiratory system disease, cardiovascular disease, Renal and Urogenital
             Disease, Gastrointestinal disease, hematological disease, Neuropsychiatric disease,
             endocrine diseases, hepatic disease or any other disease or physical condition which
             could have interfered with the interpretation of the study results

          -  Known hypersensitivity history to any prescription drug or over-the-counter medication

          -  Use of the following medications or products during the periods specified below:

        Any medication within 14 days prior to scheduled study drug administration; Alcohol and
        caffeine within 7 days prior to scheduled study drug administration; Grapefruit or
        grapefruit products within 14 days prior to scheduled study drug administration

          -  Participation in any other clinical trial within 12 weeks prior to scheduled study
             drug administration, or intention to participate any other clinical trial during the
             course of the study

          -  Significant loss or donation of blood or plasma (200 mL) within 30 days prior to the
             start of the study

          -  Body weight &lt;50kg

          -  History of drug abuse within past 5 years or positive urine drug screen results

          -  Subjects who test positive in HIV,HCV antibody,HBS antigen

          -  Otherwise judged by the investigator to be inappropriate for inclusion in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pei Hu, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology Research Center Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology Research Center Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2009</study_first_submitted>
  <study_first_submitted_qc>July 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2014</study_first_posted>
  <last_update_submitted>July 20, 2014</last_update_submitted>
  <last_update_submitted_qc>July 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2014</last_update_posted>
  <responsible_party>
    <name_title>Patiman Juma</name_title>
    <organization>Otsuka Beijing Research Institute</organization>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <keyword>imported PROBUCOL table</keyword>
  <keyword>Lorelco</keyword>
  <keyword>marketed PROBUCOL tablet</keyword>
  <keyword>Chang Tai</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Probucol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

